Name of License: Intent to Grant an Exclusive License for U.S. Government Owned Invention
Summary: : In accordance with applicable laws and regulations, announcement is made of the intent to grant an exclusive, royalty-bearing, revocable, license within a field of use.
Tech Name:
Monoclonal Antibodies that Interfere with Iron Uptake
Address: Commander, U.S. Army Medical Research and Development Command, ATTN: Director, Office of Research and Technology Applications, 1520 Freedman Drive, Suite 227, Fort Detrick, MD 21702-5012.
For Further Information Contact: Dr. David Humphrey, Office of Research & Technology Applications, (301) 619-6975. For patent issues, Ms. Leigh Callander, Supervisory Patent Attorney, (301) 619-7808.
Supplementary Information: In accordance with 35 U.S.C. 209 (e) and 37 CFR 404.7 (a)(1)(i), announcement is made of the intent to grant an exclusive within a field of use, royalty-bearing, revocable license agreement to U.S. Patent Application 18/881,793 and European Patent Application 2384370.4 entitled “Monoclonal Antibodies that Interfere with Iron Uptake” to Triari Pharmaceuticals Inc., having its principal place of business at 99 Main Street, B308, Hartford, Connecticut 06106. Anyone wishing to object to grant of this option can file written objections along with supporting evidence, if any, within 15 days from the date of this publication. Written objections are to be filed with the Director, Office of Research and Technology Applications (see ADDRESSES).